Synergistic pharmaceutical composition for topical applications

A topical pharmaceutical formulation consisting of:

• a) 1% silver sulfadiazine;
• b) 5-15 μg recombinant human epidermal growth factor (rh-EGF);
• c) 0.02% chlorhexidine gluconate (CHG);
• and
• d) one or more inactive ingredients selected from the group consisting of polyethylene glycol-30 (PEG-30), dipolyhydroxystearate, isohexadecane, C-12-15 alkyl benzoate, titanium dioxide, polyhydroxystearic acid, aluminium stearate, alumina, magnesium sulphate, stearic acid, sorbitol, methyl paraben sodium, propyl paraben sodium, sodium hydroxide, disodium EDTA, ammonium acryloyldimethylaurate, dipalmitoyl hydroxyproline, cetyl alcohol, C12-15 alkyl benzoate, caprylic/capric triglyceride, tocopheryl acetate, polyacrylamide, C13-14 isoparaffin, ethoxydiglycol, phenoxyethanol, triethanolamine, light liquid paraffin, pemulen TR-1, carbopol ultrez, mannitol, and purified water;
• wherein the topical pharmaceutical formulation is in the form of a cream or a gel or a liquid.